Hello,

Sign up to join our community!

Welcome Back,

Please sign in to your account!

Forgot Password,

Lost your password? Please enter your email address. You will receive a link and will create a new password via email.

Sorry, you do not have permission to ask a question, You must login to ask a question.

Hemangioma: A Guide to This Common Infantile Birthmark - iMedix

Hemangioma

An abstract illustration of a Hemangioma
  • 0 comments

Hemangioma

0 comments

A hemangioma represents a benign, localized overgrowth of the cells that form the inner lining of blood vessels. This proliferation results in a noncancerous vascular tumor, which most often manifests as a visible growth on or under the skin of infants. The condition is defined by a characteristic lifecycle that typically involves rapid initial growth followed by a slow, spontaneous process of regression.

What is a Hemangioma?

A hemangioma is a specific type of benign growth composed of an abnormal cluster of blood vessel cells. It forms when endothelial cells, which constitute the lining of blood vessels, proliferate excessively in one location, creating a dense, tangled mass. Although these vascular growths can technically develop on internal organs like the liver, they are most frequently identified as skin lesions in infants, typically appearing within the first few weeks after birth.

Hemangiomas are generally classified based on their location within the skin’s layers. A superficial hemangioma, often referred to as a “strawberry mark,” sits on the skin’s surface as a bright, red, raised lesion. In contrast, a deep hemangioma develops in the underlying layers, presenting as a bluish or skin-colored swelling with a less distinct border. A compound hemangioma exhibits features of both, with a superficial red component overlying a deeper bluish mass.

A defining characteristic of most infantile hemangiomas is their predictable life cycle. They typically undergo a period of rapid expansion during the first few months of life, followed by a stabilization phase, and then a prolonged period of slow, natural regression (involution) over several years.

Causes:
The precise trigger for the development of a hemangioma remains unknown, and the condition is not considered to be directly inherited in most cases. Research points to a malfunction in the normal process of blood vessel formation (vasculogenesis) during fetal development. Several leading theories attempt to explain this abnormal cell proliferation.
  • Placental Cell Origin: A prominent theory suggests that hemangiomas may arise from placental cells that migrate and implant within the developing skin of the fetus. These misplaced cells, which share biological markers with placental tissue, are then believed to proliferate abnormally after birth.
  • Localized Hypoxia: Another hypothesis proposes that a temporary state of low oxygen (hypoxia) in a small patch of fetal tissue may be the trigger. This oxygen deficit is thought to activate certain genetic pathways that command blood vessel cells to multiply rapidly in a misguided attempt to improve blood supply to the area.
  • Hormonal Influence: The fact that hemangiomas are significantly more common in female infants points to a potential role for hormones. It is theorized that estrogen may promote the growth and proliferation of the endothelial cells that form these vascular growths.
  • Somatic Mutations: While not typically passed down through families, some hemangiomas may be caused by a somatic mutation. This is a genetic change that occurs by chance in a single cell after conception, which then directs that cell and all its descendants to grow into a vascular mass.
Risk Factors:
The likelihood of an infant developing a hemangioma is not entirely random; specific characteristics associated with the infant and the pregnancy correlate with a greater incidence. The following factors are consistently linked to a higher probability of this condition.
  • Female Gender: For reasons that are still being investigated, female infants are diagnosed with hemangiomas at a rate that is three to five times higher than that of male infants, making gender the most pronounced risk factor.
  • Low Birth Weight: A baby's weight at birth is a significant predictor. Infants born with a lower-than-average weight, particularly those weighing less than 2.2 pounds (1 kg), have a substantially increased chance of developing one or more hemangiomas.
  • Premature Birth: Infants born before their full term are more susceptible. The risk increases with the degree of prematurity, meaning babies born earlier in the gestational period are more likely to have these vascular growths.
  • Caucasian Ancestry: There is a clear demographic link related to ethnicity. Infants of Caucasian descent have a higher reported incidence of developing hemangiomas when compared to infants from other racial backgrounds, such as those of African or Asian ancestry.
  • Multiple Gestation Pregnancies: Being part of a twin, triplet, or other multiple birth is also associated with an elevated risk. This may be linked to shared placental factors or the lower average birth weights common in these pregnancies.

Commonly Used Medications for Hemangioma

Treatment is often unnecessary as most hemangiomas resolve on their own. However, for those that are large, fast-growing, or located in a high-risk area (like near the eye), medication may be used to halt growth and speed up regression.

  • Propranolol: This oral beta-blocker is the first-line treatment for problematic infantile hemangiomas, working by narrowing the blood vessels within the growth.
  • Timolol Maleate: A beta-blocker applied topically as a gel or solution, this medication is effective for smaller, thinner, superficial hemangiomas.
  • Systemic Steroids (Prednisolone): Once a common therapy, oral steroids are now typically reserved for cases where beta-blockers are not effective or cannot be used.

Where to Find More Information?

Support

  • Vascular Birthmarks Foundation (VBF): This is a key international organization providing support, sponsoring research, and connecting families affected by hemangiomas and other vascular anomalies with medical experts. https://birthmark.org/
  • Pediatric Dermatology Centers: Specialized clinics within children’s hospitals offer integrated support, providing expert diagnosis, management plans, and access to the latest treatments for complex hemangiomas.
  • Online Parent Support Groups: Numerous private groups on social media platforms like Facebook provide a community for parents to share experiences, photos, and emotional support throughout their child’s hemangioma journey.

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.

  • Q&A
There are no questions!

You must login to add a comment.

Thank you for sharing your valuable feedback and experiences related to Suhagra 100 Tablet, your inputs will help many others in their health journey.

Ask to get answers.

Claim your

By clicking the button below, you accept WebMD's terms of use and
privacy policy. All fields are required unless designated as optional.